A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40 mg modified-release capsules versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea

Psoriasis

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study

J Am Acad Dermatol.

Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, Kianifard F, Nyirady J, Lebwohl M

doi: 10.1016/j.jaad.2017.05.033.

Rosacea

Use of an Alternative Method to Evaluate Erythema Severity in a Clinical Trial: Difference in Vehicle Response With Evaluation of Baseline and Postdose Photographs for Effect of Oxymetazoline Cream 1.0% for Persistent Erythema of Rosacea in a Phase 4 Study

Br J Dermatol.

Eichenfield LF, Del Rosso JQ, Tan JKL, Hebert AA, Webster GF, Harper J, Baldwin HE, Kircik LH, Stein-Gold L, Kaoukhov A, Alvandi N

doi: 10.1111/bjd.17462.

Atopic Dermatitis

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Lancet.

Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B

doi: 10.1016/

Atopic Dermatitis

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

Br J Dermatol.

de Bruin-Weller M, Thaçi D, Smith CH, Reich K, Cork MJ, Radin A, Zhang Q, Akinlade B, Gadkari A, Eckert L, Hultsch T, Chen Z, Pirozzi G, Graham NMH6, Shumel B

doi: 10.1111/bjd.16156.

Further Publications Dermatology

A 1% glycopyrronium bromide cream for the topical treatment of primary axillary hyperhidrosis: Efficacy and Safety Results from a Phase 3a Randomised Controlled Study

Br J Dermatol

Abels C, Soeberdt M, Kilic A, Reich H, Knie U, Jourdan C, Schramm K, Heimstaedt-Muskett S, Masur C, Szeimies RM

doi: 10.1111/bjd.19810

Acne

Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials

JAMA Dermatol.

Hebert A, Thiboutot D, Stein Gold L, Cartwright M, Gerloni M, Fragasso E, Mazzetti A

doi: 10.1001/jamadermatol.2020.0465.

Rosacea

A Multicenter, Randomized, Double-Masked, Parallel Group, Vehicle-Controlled Phase 2b Study to evaluate the safety and efficacy of 1% and 3% topical Minocycline Gel in patients with Papulopustular Rosacea

Br J Dermatol.

Webster G, Draelos ZD, Graber E, Lee MS, Dhawan S, Salman M, Magrath GN

doi: 10.1111/bjd.18857.

Acne

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies

J Am Acad Dermatol.

Gold LS, Dhawan S, Weiss J, Draelos ZD, Ellman H, Stuart IA

doi: 10.1016/j.jaad.2018.08.020.

Psoriasis

Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study

J Am Acad Dermatol.

Van Voorhees AS, Gold LS, Lebwohl M, Strober B, Lynde C, Tyring S, Cauthen A, Sofen H, Zhang Z, Paris M, Wang Y

doi: 10.1016/j.jaad.2020.01.072.

Related content

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study

Use of an Alternative Method to Evaluate Erythema Severity in a Clinical Trial: Difference in Vehicle Response With Evaluation of Baseline and Postdose Photographs for Effect of Oxymetazoline Cream 1.0% for Persistent Erythema of Rosacea in a Phase 4 Study

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)

A 1% glycopyrronium bromide cream for the topical treatment of primary axillary hyperhidrosis: Efficacy and Safety Results from a Phase 3a Randomised Controlled Study

Efficacy and Safety of Topical Clascoterone Cream, 1%, for Treatment in Patients With Facial Acne: Two Phase 3 Randomized Clinical Trials

A Multicenter, Randomized, Double-Masked, Parallel Group, Vehicle-Controlled Phase 2b Study to evaluate the safety and efficacy of 1% and 3% topical Minocycline Gel in patients with Papulopustular Rosacea

A novel topical minocycline foam for the treatment of moderate-to-severe acne vulgaris: Results of 2 randomized, double-blind, phase 3 studies

Efficacy and Safety of Apremilast in Patients With Moderate to Severe Plaque Psoriasis of the Scalp: Results of a Phase 3b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study